Oncor disappears from the Amex:
This article was originally published in Clinica
Oncor, the troubled gene-based diagnostic company, has had its shares suspended indefinitely from the American Stock Exchange (AMEX). AMEX had already applied to the Securities and Exchange Commission to remove Oncor from the market - a move that Oncor had opposed. Now, Oncor's failing liquidity (see Clinica No 828, p 9) has prompted the delisting. It is not known whether the Gaithersburg, Maryland, company will attempt to get a quote on one of the alternative markets.